The calibration curve for L-carnitine in serum was linear between 5 and 250 pmol/L. Analytical recovery was 96.5-106%, and within-run and between-run imprecisions (CV) were 0.66-4.33% and 1.02-2.56%, respectively. This method was free from interference by bilirubin, hemoglobin, various acyl-DL-carnitines, and ascorbate. The procedure is simple, rapid, accurate, and automatable. The amount of free L-carnitine in serum (53.6 ± 11.7 mol/L, n = 200) was greater in men than in women (45.1 ± 14.2 pmol/L, n = 200) (mean ± SD). we added ammonium sulfate to the cell-free extract to 45% saturation and removed the precipitate by centrifugation. The precipitate formed by the further addition of ammonium sulfate to 55% saturation was collected and dialyzed against 20 mmol/L Tris-HC1 buffer (pH 8.0). We then applied the dialyzed enzyme solution to a 3.8 x 20 cm Q-Sepharose column (Pharmacia, Uppsala, Sweden) equffibrated with 20 mmol/L Tris-HC1 buffer (pH 8.0), and eluted the CDH with a lineargradientofKC1 in the same buffer. CDH fractions were collected and dialyzed against 20 mmol/L Trisacetate buffer (pH 6.5). The dialyzed CDH was applied on a 3.8 x 10 cm hydroxyapatite column (Asahi Optical Co., Tokyo, Japan) equilibrated with same buffer. After
Indexing Terms: enzymatic methods/thio-NADH L-Carnitine is an essential substance that acts as a mediator for fatty acid transport through the mitochondrial membrane prior to intracellular /3-oxidation; hence, a deficiency of L-carnitine causes disorders in fatty acid and its related metabolisms (1-9). In particular, a deficiency in L-carnitine is believed to cause disorders of skeletal muscle and cardiac muscle, both of which are high-energy-consuming tissues (2, 10, 11).
Inborn errors of L-carnitine metabolism have been studied (12-14) and, recently, secondary disorders of L-carnitine metabolism have become a problem in patients with nephrosis or undergoing dialysis (15) (16) (17) (18) (19) (20) . To study the behavior of L-carnitine in disease and therapy, investigators need a simple, rapid, and specific assay of L-carnitine in biological samples.
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Results

EnzymaticCyclingAssay of L-Carnitine
Except as otherwise mentioned, the assay procedure was as follows: We incubated at 37#{176}C 1 mL of 100 mmol/L Tnis-HC1 buffer (pH 9.5), 5 mmol/L thio-NAD, 0.2 mmol/L NADH, and 100 kU/L CDII in a 10-mmpathlength cuvettefor 3 min. To start the enzyme reaction, we added 50 L of serum specimen or of 50 moI/L L-carnitine standard solution. We measured the absorbance at 415 rim and calculated the difference between the measurements made 1 and 6 mm after the start of 
The 50 tmoI/L carnitine standard was prepared in deionized water and adjusted to pH 7.0 with NaOH.
DTNB Assay of L-Carnitine
The DTNB assay procedure was as follows: To 1 mL of 100 mmoLIL Tris-HC1 buffer (pH 7. 
Instrumentation
We used a Model UV-250 (Shimadzu Seisakusho Co., Kyoto, Japan) spectrophotometer and a Cobas-Fara analyzer (Roche Co., Nutley, NJ).
Optimization of the cycling reaction.
We studied the effects of pH and the concentration of components involved in the cycling reaction mixture.
Because the responses for L-carnitine in Tnis-HC1 buffer were better than in the other tested buffersolutions, we used Tris-HC1 buffer to test optimum pH (Fig. 1) . The cycling reaction was most sensitive at pH 9.5.
The concentration of NADH also affected the velocity of the cycling reaction (Fig. 2) run imprecision was also satisfactory ( Table 2) . We observed no effect on the cycling reaction from bilirubin (<500 mgfL), hemoglobin (<5 g/L), ascorbate (<1000 mg/L), or various acyl-DL-carnitines (<500 mmolfL): acetyl-DL-carflitine, DL-hexanoyl carnitine, DL-octanoyl carnitine, DL-decanoyl carnitine,
DL-lauroyl
carnitine, DL-myristoyl carnitine, palniitoyl-DL-carnitine, and DLstearoyl carnitine.
The amount of free L-carnitine in serum (mean ± SD) was greater in men (53;6 ± 11.7 moI/L, n = 200) than in women (45.1 ± 14.2 j.mo1IL, n = 200), as determined with the Cobas Fara.
Assays of L-carnitine solution by the enzyme cycling method and the DTNB method (21,26) correlated well, as did the determination of free L-carnitine in serum by both methods (Fig. 3) . 
radioactivity.
The previous CDH method measures NADH production (22), which has low molar absorptivity at 340 nm, making it difficult to assay serum L-carmtine in a patient with L-carnitine-deflcient disease; moreover, the NADH produced is consumed by another dehydrogenase, which thus causes erroneous measurements. All of these methods are also insufficiently sensitive to quantify L-carnitine in small volumes of serum, e.g., 20-L collections from premature infants. of CDH, and the reagent stability is dependent on the purity and stability of CDH used.
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